AUMC joined our Cure4Life consortium

The AUMC team, Lotte Haverman PhD, Hedy van Oers PhD and Lorynn Teela PhD, is contributing to work package 5 of the project, which focuses on understanding the well-being of parents whose children may be eligible for gene therapy. In this context, the AUMC team will start by identifying patient reported outcomes (PROs) that are important for this group, so that they can develop a core outcome set. Next, they will explore changes and challenges in parental well-being during the gene therapy process using the patient reported outcome measure (PROM) core set. The team is excited to work together with Meike Bartels and Esmée van Zon to contribute to this important project.